All Articles
The full research library.
FDA Panel's Peptide Vote: Easier Tesamorelin Access and Off-Label Metabolic Prescribing
An FDA panel vote to ease Tesamorelin access could reshape off-label metabolic prescribing, as research on peptides like Retatrutide surges and
Retatrutide Compounding Under Scrutiny as FDA Warns on GLP-1 Weight Loss Drugs
Retatrutide compounding faces FDA warnings as demand surges for the triple-hormone agonist. Bibliometric data show a 340% publication increase, but
Tesamorelin Off-Label Prescribing Looms as FDA Panel Eases Peptide Access
Tesamorelin off-label prescribing surges after an FDA panel vote eases peptide access. Researchers explore visceral-fat reduction beyond HIV
FDA Cites Compounding Pharmacies for Retatrutide Impurities as GLP-1 Triagonist Demand Surges
The FDA issued a Form 483 to a Florida compounding pharmacy after finding impurities in retatrutide, a GLP-1 triagonist. The citation highlights quality
Retatrutide Liver Fat Data Under FDA Review: Off-Label Recomposition Implications
Retatrutide's liver fat clearance data is under FDA priority review, sparking off-label interest in body recomposition. We examine the evidence, costs, and